StockData
Zomedica Corp. logo

Zomedica Corp. (ZOMDF) company profile

ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$0.08−0.00 (-0.55%)

Close on Oct 19, 2026Market cap $77.40MP/E –Yield –

About Zomedica

Pharmaceutical Preparations, SIC 2834

Zomedica Corp. is an animal health company that develops, manufactures, and markets diagnostic and therapeutic medical devices for companion animals, including dogs, cats, and horses. Its diagnostic offerings include the TRUFORMA point-of-care acoustic wave testing platform, the TRUVIEW automated digital microscopy and cytology system, and the VETGuardian zero-touch vital signs remote monitoring device. Its therapeutic portfolio features PulseVet electrohydraulic shockwave therapy equipment, Assisi targeted pulsed electromagnetic field devices, and VETIGEL hemostatic gel. The company primarily serves clinical veterinarians, veterinary practices, and pet owners.

The company operates manufacturing and distribution facilities in Roswell, Georgia, and a research, development, and manufacturing center in Plymouth, Minnesota. It serves clinical customers in the United States directly through internal sales representatives and domestic distributors. Outside the United States, it commercializes therapeutic products through international distribution networks and a wholly owned subsidiary in Japan. The provided text specifies operational facilities but does not identify the city or address of the corporate headquarters.

Summary of the business section of Zomedica's latest annual report, written by StockData.

Company profile

Company

Legal name
Zomedica Corp.
Founded
2013
Headquarters
Ann Arbor, MI
Address
1101 Technology Drive, Suite 100 48108
Phone
(734) 369-2555
Employees
141, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
A0
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Southfield, Michigan

Stock & identifiers

Ticker
ZOMDF
Former tickers
ZOM until Mar 5, 2025
Exchange
OTC
IPO date
Nov 21, 2017
Shares outstanding
980M, Aug 5, 2026
Public float
$38.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1684144
CUSIP
98980M109
ISIN
CA98980M1095
FIGI
BBG00DGZC7Y0
Share class FIGI
BBG004H67DQ5
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Larry C. Heaton IiCEO, Director1,250,000
Anthony K. BlairCOO1,000,000
Karen DeHaan-FullertonGeneral Counsel104,300
Russell Kevin KlassSr Vice President, Sales6,105,000
Scott JordanChief Financial Officer300,000
Christopher Ross MacleodDirector143,000
Pamela NicholsDirector–
Sean WhelanDirector–
Johnny D. PowersDirector4,425,000
Jeffrey M. RoweDirector13,116,127
Robert CohenDirector543,750
Rodney James WilliamsDirector301,900

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2023$651.40K$1.03M$643.19K$86960–
FY2022$1.34M-$128.92K$732.81K$70870–
FY2021$5.10M$2.63M$415.08K$133480–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Larry Heaton
Chief Executive Officer
$466.40K$147.27K$149.21K$762.88K–
Mike Zuehlke
Sr. VP of Finance and Controller(3)
$247.50K$69.36K$37.53K$354.39K–
Tony Blair
Chief Operating Officer
$275.53K$86.65K$27.98K$390.15K+6%
Kevin Klass
Sr. VP of Sales
$286.40K$113.00K$34.00K$433.40K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 21, 2017
Exchange
NYSE American
First trading day
Nov 21, 2017
First-day close
$2.39
Lock-up ends (est.)
May 20, 2018

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 141 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?